Teva combats generics counterfeiting ring in Europe; AstraZeneca appeal in Seroquel case denied;

 @FiercePharma: ICYMI yesterday: Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore. More | Follow @FiercePharma

> Teva Pharmaceutical Industries ($TEVA) said it's stepping up quality inspections in Europe after discovering counterfeit versions of its omeprazole stomach acid drug, a generic copy of AstraZeneca's ($AZN) Prilosec. Report

> An appeals court upheld the FDA's decision to deny AstraZeneca extended exclusivity for its antipsychotic drug Seroquel. Report

> European regulators backed Roche's ($RHHBY) skin cancer treatment Erivedge and Astellas Pharma's prostate cancer drug Xtandi. Report

> U.K. union leaders are meeting with AstraZeneca executives in a bid to persuade the company not to close an R&D site in Alderley Park and move some 2,000 jobs. Report

> The European Medicines Agency recommended suspending use of all drugs containing tetrazepam, an off-patent anxiety and insomnia treatment, after reports of serious skin reactions. Report

> China's Fosun Pharma has agreed to buy Israeli laser maker Alma Lasers for up to $240 million. Report

Medical Device News

@FierceMedDev: Touch-sensitive robot arm envisioned, in part, as patient care device. Item | Follow @FierceMedDev

@MarkHFierce:  We had a fruitful week at BIO 2013 in Chicago. Check out the highlights. Slideshow | Follow @MarkHFierce

 @DamianFierce: In case you missed it over the weekend, Quintiles finally priced its IPO, seeking $790M. News | Follow @DamianFierce

> Bayer to grab birth control device maker Conceptus for $1.1B. Story

> Judge tosses Smith & Nephew hip lawsuit. More

> RainDance draws Myriad Genetics into $20M Series E. Article

Biotech News

@FierceBiotech: ICYMI: Johnson & Johnson, Evotec bask in Harvard's breaking diabetes discovery. Story | Follow @FierceBiotech

@JohnCFierce: Union wants AstraZeneca to rethink the big Cambridge move, but I don't see it. A reversal would look like schizophrenia. Article | Follow @JohnCFierce

@RyanMFierce: Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore. Story | Follow @RyanMFierce

> U.K. union makes its case against AstraZeneca's R&D relocation. Item

> Giants team on diabetes as Merck partners with Pfizer on SGLT2 combo. News

> Celgene taps biotech Forma for drugs in hot field of protein homeostasis. Article

> Guidelines for contributing an Industry Voices column to Fierce. Publisher's note

CRO News

> AMRI inks 5-year CDMO deal with Ono. Story

> Biocon's CRO now largest in India. Article

> Catalent quadruples biologics capacity with new plant. More

> Icon's revenue soars 26% in Q1. Report

Biotech IT News

> AZ helps NHS develop social media app for U.K. market. More

> Medidata's profit up 51% in Q1 compared to last year as customer base grows. Report

> 'Jeff Bezos of bioinformatics' finds capital and customers for startup. Story

> Treato scores $14.5M VC round, tackles social media analytics for pharma. Article

> Mining clinical notes could detect harmful drug reactions earlier. News

And Finally... The day of the diagnostic dashboard doctor may not be too far off. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.